PMID: 9529080Apr 7, 1998Paper

Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule

Infection and Immunity
T R KozelK K Wall

Abstract

Encapsulated cells of Cryptococcus neoformans are potent activators of the alternative complement pathway. Previous studies found that monoclonal antibodies (MAbs) specific for the major capsular polysaccharide, termed glucuronoxylomannan (GXM), can markedly suppress the ability of the capsule to accumulate C3 from normal human serum via the alternative pathway. The present study examined the abilities of F(ab)2 and Fab fragments of three MAbs (MAbs 439, 3C2, and 471) to mediate the suppressive effect. The results showed that F(ab)2 fragments of all three MAbs suppressed activation and binding of C3 via the alternative pathway in a manner similar to that of intact antibodies. In contrast, Fab fragments of MAb 439 and MAb 3C2 showed no suppressive activity, and Fab fragments of MAb 471 were markedly reduced in suppressive activity. Indeed, there was an earlier accumulation of C3 on encapsulated cryptococci in the presence of the Fab fragments. Study of subclass switch families of MAb 439 and MAb 471 found that MAbs of an immunoglobulin G (IgG) subclass with increased flexibility in the hinge region (IgG2b) had less suppressive activity than MAbs of IgG subclasses with less flexibility (IgG1 or IgG2a). Taken together, these resul...Continue Reading

References

Apr 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·D T Fearon, K F Austen
May 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·M K Pangburn, H J Müller-Eberhard
Feb 28, 1978·Biochemical and Biophysical Research Communications·P J Fraker, J C Speck
Nov 1, 1992·Infection and Immunity·J MukherjeeA Casadevall
Jan 1, 1981·The Biochemical Journal·R B SimE Sim
Jan 1, 1995·The Journal of Experimental Medicine·J MukherjeeA Casadevall
Aug 1, 1994·Antimicrobial Agents and Chemotherapy·A Casadevall, M D Scharff
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J MukherjeeA Casadevall
Jan 1, 1996·Clinical Microbiology Reviews·T R Kozel
Feb 17, 1997·The Journal of Experimental Medicine·G NussbaumP Valadon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.